Key Developments: Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

1,003.75INR
22 May 2015
Change (% chg)

Rs22.50 (+2.29%)
Prev Close
Rs981.25
Open
Rs978.00
Day's High
Rs1,008.90
Day's Low
Rs976.75
Volume
4,813,876
Avg. Vol
8,080,609
52-wk High
Rs1,200.80
52-wk Low
Rs572.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sun Pharmaceutical Industries Ltd settles Angiomax litigation with The Medicines Company - The Economic Times
Wednesday, 1 Apr 2015 11:28am EDT 

Sun Pharmaceutical Industries Ltd:Has entered into a settlement pact with The Medicines Company for settling the lawsuit filed against it by the later for generic Angiomax - The Economic Times.The company and certain of its subsidiaries have executed a settlement agreement with The Medicines Company settling the lawsuit filed against the company and its subsidiaries regarding submission of ANDA by one of subsidiaries, for a generic version of Angiomax, Bivalirudin injection.Under the terms of the agreement, the company's subsidiary is entitled to launch its version of generic Angiomax in the US on June 30, 2019 or earlier under certain limited circumstances.  Full Article

Sun Pharmaceutical Industries Ltd announces closure of merger deal with Ranbaxy
Wednesday, 25 Mar 2015 07:29am EDT 

Sun Pharmaceutical Industries Ltd:Begins integration of Ranbaxy's business following closure of its merger.Says integration, planned by Sun Pharma over many months, will focus on supporting strong growth.Says merger has fortified Sun Pharma's position as world's fifth largest specialty generic pharmaceutical company and top ranking Indian Pharma company with significant lead in market share.Says combined entity's manufacturing footprint covers 5 continents with products sold in over 150 nations with stronger presence in US, India, Asia, Europe, South Africa, CIS & Russia and Latin America.Sun Pharma now offers large basket of specialty and generic products encompassing a broad range of chronic and acute prescription drugs as well as a ready foray into the global consumer healthcare market.Post-merger, Daiichi Sankyo becomes the second largest shareholder in Sun Pharma and both companies will work together to leverage this relationship for global business growth.Says integrated culture theme, "Growing Together", represents the core objective of this merger focusing on improving productivity, compliance commitment, focus on quality and sustainable growth.Through this merger Sun Pharma emerges as India's first truly global pharmaceutical company.  Full Article

Sun Pharmaceutical Industries Ltd recalls 5,322 bottles of Ketorolac eye drop in US - The Economic Times
Sunday, 8 Mar 2015 01:13am EST 

Sun Pharmaceutical Industries Ltd:Is voluntarily recalling 5,322 bottles of Ketorolac Tromethamine ophthalmic solution in the US market for failing to meet specifications - The Economic Times.As per the information available on the USFDA website, Sun Pharma Global Fze, a US-based unit of the company, is recalling the eye drops for 'presence of particulate matter' in the 5,322 batch of bottles.The drug was manufactured by Sun Pharmaceutical Industries at its Halol facility in Gujarat and distributed by Caraco Pharmaceutical Laboratories in the US market.The recall was initiated by the company on Jan. 21 this year.It has been classified as a 'Class-II recall.  Full Article

Sun Pharmaceutical Industries Ltd to buy GlaxoSmithKline Plc's Opiates business in Australia
Monday, 2 Mar 2015 09:48pm EST 

GlaxoSmithKline Plc and Sun Pharmaceutical Industries Ltd:Announced that their respective wholly owned subsidiaries have reached an agreement related to GSK's Opiates business in Australia.Current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, will transfer to a subsidiary of Sun Pharma.Product portfolio consists of poppy-derived opiate raw materials that are primarily used in manufacture of analgesics for treatment of moderate to severe pain.Says that all employees from both sites will also be offered employment by Sun with the Opiates business.Financial terms of transaction are confidential.Transaction is expected to close by Aug.  Full Article

Sun Pharmaceutical Industries Ltd updates on scheme of arrangement for Ranbaxy Laboratories Ltd
Monday, 24 Nov 2014 03:37am EST 

Sun Pharmaceutical Industries Ltd:Says the Hon'ble High Court of Gujarat, on Nov. 14, has sanctioned the scheme of arrangement in the nature of merger of Ranbaxy Laboratories Ltd with Sun Pharmaceutical Industries Ltd pursuant to its oral order uploaded on the web site of Hon’ble High Court of Gujarat on Nov. 21.  Full Article

Sun Pharmaceutical Industries Ltd and Merck & Co. Inc. enter into licensing agreement for Tildrakizumab
Wednesday, 17 Sep 2014 08:30am EDT 

Sun Pharmaceutical Industries Ltd and Merck & Co. Inc:Says through their respective subsidiaries, announced an exclusive worldwide licensing agreement for Merck's investigational therapeutic antibody candidate, tildrakizumab.Under terms, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of US$80 mln.Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma.Transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.  Full Article

Sun Pharmaceutical Industries Ltd's Caraco Pharmaceutical initiates recall of cephalexin capsules-Business Standard
Monday, 18 Aug 2014 03:25am EDT 

Sun Pharmaceutical Industries Ltd:Caraco Pharmaceutical Laboratories, the US-based unit of Sun Pharmaceuticals, has initiated a recall of multiple lots of cephalexin capsules from the US market, according to a PTI report-Business Standard.Citing a notification by the USFDA, the report says that the recall of the 340,553 units of 500 mg and 113,677 units of 250 mg bottles is voluntarily initiated by the company through a letter to the regulator in June under 'Class-II' classification.  Full Article

Sun Pharmaceutical Industries Ltd recommends payment of dividend
Tuesday, 12 Aug 2014 10:58pm EDT 

Sun Pharmaceutical Industries Ltd:Says board of Directors of the company have recommended payment of dividend of 1.50 indian rupees for the year ended Mar.31, 2014.  Full Article

Sun Pharmaceutical Industries Ltd Appoints Chief Financial Officer
Tuesday, 12 Aug 2014 10:45pm EDT 

Sun Pharmaceutical Industries Ltd:Appoints Uday Baldota as Chief Financial Officer (CFO) of Company with immediate effect.  Full Article

Sun Pharmaceutical Industries Ltd's subsidiary acquires Pharmalucence Inc
Tuesday, 15 Jul 2014 11:34pm EDT 

Sun Pharmaceutical Industries Ltd:Announces acquisition of Pharmalucence Inc, by one of its subsidiaries.Pharmalucence has sterile injectable capacity in the US, supported by R&D capabilities.Terms of the acquisition were not disclosed.  Full Article

Indian court bars Glenmark from selling Merck drug copies

MUMBAI - India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday.

Search Stocks